Clinical Trials

PhaseBio is exploring the potential benefit of our investigational therapies in clinical trials, in order to confirm their mechanisms of action in humans, to investigate their side effects and to understand the characteristics of those patients most likely to benefit.

Our lead therapy, PB1046, is being evaluated in two clinical studies: a phase 2a multiple ascending dose study in patients with heart failure and an exploratory individually dose-titrated study in subjects with pulmonary arterial hypertension (PAH).  PhaseBio expects to initiate a larger, placebo-controlled phase 2 clinical study of PB1046 in PAH in the first half of 2018.

PhaseBio strives to work closely with patients and the scientific and regulatory communities to rapidly advance our pipeline and to identify new therapeutic applications that may benefit from our ELP biopolymer technology.